AmeriPharma’s premier pharmacy services are available in multiple states throughout the US.
Mon - Fri: 9:00AM - 10:00PM Sat - Sun: Closed

Related Posts

Welcome to Infusion Center

Myasthenia Gravis Symptoms and Complications

Home  /  Myasthenia Gravis   /  Myasthenia Gravis Symptoms and Complications
Myasthenia Gravis Symptoms and Complications

Signs and Symptoms of Myasthenia Gravis

The onset of myasthenia gravis (MG) may be sudden and oftentimes difficult to diagnose as the symptoms aren’t immediately recognized as myasthenia gravis.


Get IVIG Copay Assistance – Speak to a Specialist


Myasthenia gravis may affect the voluntary muscles in our bodies. These muscles are responsible for controlling eye and eyelid movement, facial expression, and swallowing. In most cases, initial noticeable symptoms include weakness of the eye muscles, difficulty in swallowing, and slurred speech. However, the degree of muscle weakness involved in myasthenia gravis varies greatly among patients. 

Depending on the type and severity, the symptoms may include a drooping of one or both eyelids (ptosis); blurred or double vision (diplopia) due to weakness of the muscles that control eye movements; unstable or waddling gait; weakness in arms, hands, fingers, legs, and neck; a change in facial expression; difficulty in swallowing and shortness of breath; and impaired speech (dysarthria).


Can IVIG help? | Free IVIG Treatment Info


Complications of Myasthenia Gravis

Myasthenic Crisis

Myasthenic crisis is a potentially life-threatening complication of MG. About one in five people with MG may develop myasthenic crisis at least once in their lifetime. It occurs when your respiratory muscles become too weak to support breathing. If left untreated, a myasthenic crisis can result in respiratory failure and death.


Contact Us

By submitting, you agree to AmeriPharma’s Terms of UsePrivacy Policy, and Notice of Privacy Practice



  2. Basta, Ivana et al. “Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia.” Muscle & nerve vol. 58,5 (2018): 708-712. doi:10.1002/mus.26132.
  3. Christensen PB, Jensen TS, Tsiropoulos I, et al Mortality and survival in myasthenia gravis: a Danish population based study, Journal of Neurology, Neurosurgery & Psychiatry 1998;64:78-83.
  4. Alshekhlee, A et al. “Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.” Neurology vol. 72,18 (2009): 1548-54. doi:10.1212/WNL.0b013e3181a41211.
  5. Wendell, Linda C, and Joshua M Levine. “Myasthenic crisis.” The Neurohospitalist vol. 1,1 (2011): 16-22. doi:10.1177/1941875210382918.
  6. Twork, S., Wiesmeth, S., Klewer, J. et al. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 8, 129 (2010).
  7. Szczudlik, Piotr et al. “Determinants of Quality of Life in Myasthenia Gravis Patients.” Frontiers in neurology vol. 11 553626. 23 Sep. 2020, doi:10.3389/fneur.2020.553626.


This information is not a substitute for medical advice or treatment. Talk to your doctor or healthcare provider about your medical condition prior to starting any new treatment. AmeriPharma Specialty Care assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result, nor is it responsible for the reliability of the content.

AmeriPharma Specialty Care does not operate all the websites/organizations listed here, nor is it responsible for the availability or reliability of their content. These listings do not imply or constitute an endorsement, sponsorship, or recommendation by AmeriPharma Specialty Care.

This webpage may contain references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with AmeriPharma Specialty Care.